Purchase Short-Term Access

Rivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatment

James Douketis, MD

Annals of Internal Medicine 2011;154:JC5-6. doi:10.7326/0003-4819-154-10-201105170-02006

Purchase Online access to this article for 24 hours

Annals of Internal Medicine

Forgot Your Password?

to gain full access to the content and tools.

Learn more about subscription options

Forgot your password?

Enter your username and email address. We'll send you a reminder to the email address on record.

Username* (Required)

Email Address* (Required)